Article Information
History
- November 3, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Jeroen H.A. Creemers1,4,
- Willem J. Lesterhuis3,
- Niven Mehra2,
- Winald R. Gerritsen2,
- Carl G. Figdor1,4,
- I. Jolanda M. de Vries1 and
- Johannes Textor1,5,*
- 1Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences; Radboudumc, Nijmegen, The Netherlands
- 2Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands
- 3School of Biomedical Sciences and Telethon Kids Institute, University of Western Australia, Perth, Australia
- 4Oncode Institute, Nijmegen, The Netherlands
- 5Data Science Department, Institute for Computing and Information Sciences, Radboud University, Nijmegen, The Netherlands
- ↵*Corresponding author: Dr. J. Textor, Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc, Geert Grooteplein 26, 6500 HB Nijmegen (P.O. Box 9101), The Netherlands, E-mail: johannes.textor{at}radboudumc.nl
Posted November 03, 2020.
A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery
